AIM Vaccine Co., Ltd. (6660.HK)

7.180 +0.080 (+1.13%) At close: 03:59PM HKT

AIM Vaccine Co., Ltd.

Tower A, Gemdale Plaza
Unit 2505-2507, 25th Floor 91 Jianguo Road Chaoyang District
Beijing
China

https://www.aimbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,624

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Yan Zhou	Executive Chairman & CEO	2.34M	N/A	1967
Mr. Xin Zhou	Executive Vice-Chairman of the Board	N/A	N/A	1970
Mr. Wen Guan	Vice-Chairman of the Board & Executive President	2.39M	N/A	1968
Mr. Shaojun Jia	COO, Executive President & Executive Director	2.62M	N/A	1964
Ms. Lixin Niu	Chief Financial Officer	N/A	N/A	1972
Ms. Ling Liu	Secretary & Chief Investment Officer	N/A	N/A	1984
Mr. Zhang Fan	Chief Research Officer	N/A	N/A	1987
Ms. Meng Li	Chief Quality Officer	N/A	N/A	1965
Ms. Zhou Wenjuan	Chief Public Affairs Officer	N/A	N/A	1979
Mr. Lin Zhenyu	Chief Marketing Officer	N/A	N/A	1975

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

AIM Vaccine Co., Ltd. researches, develops, manufactures, and commercializes of vaccine products for human use in the People's Republic of China. The company's product pipeline includes tetravalent meningococcal conjugate vaccine, that is in phase IV clinical trials indicated for meningococcal disease 13-Valent pneumonia Conjugate and 23-valent pneumonia Polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine which is in phase III clinical trials to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, that is in phase II trials for the treatment of meningococcal disease; EV71-CA16 Bivalent HFMD vaccine. In addition, the company develops 20-valent and 24-valent pneumonia conjugate vaccine, haemophilus influenzae type b conjugate vaccine, absorbed tetanus vaccine, quadrivalent influenza virus vaccine (MDCK Cells), and human diploid rabies vaccine. Further, it offers hexavalent meningococcal vaccine to treat meningococcal disease; hexavalent group b streptococcus polysaccharide conjugate vaccine; mRNA human rabies vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; diphtheria, tetanus and pertussis and haemophilus influenzae type b, and diphtheria, tetanus and acellular pertussis combination vaccine for the treatment of DTP; and recombinant group b meningococcal vaccine to treat meningococcal disease. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. The company was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

Corporate governance

AIM Vaccine Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.